MiR-223 regulates autophagy associated with cisplatin resistance by targeting FBXW7 in human non-small cell lung cancer

BACKGROUND: Cisplatin is widely used as a first-line treatment for non-small cell lung cancer (NSCLC), but chemoresistance remains a major clinical obstacle for efficient use. As a microRNA, miR-223 was reported to promote the doxorubicin resistance of NSCLC. However, whether miR-223 is also involve...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui, Chen, Jiabin, Zhang, Shufen, Zheng, Xiaoxiao, Xie, Shangzhi, Mao, Jiayan, Cai, Ying, Lu, Xuemei, Hu, Liqiang, Shen, Jian, Chai, Kequn, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304223/
https://www.ncbi.nlm.nih.gov/pubmed/32577098
http://dx.doi.org/10.1186/s12935-020-01284-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304223/
https://www.ncbi.nlm.nih.gov/pubmed/32577098
http://dx.doi.org/10.1186/s12935-020-01284-x

Ejemplares similares